Lisata Therapeutics Announces EMA LSTA1 Orphan Drug Designation for Pancreatic Cancer Treatment
The designation will grant Lisata EU marketing exclusivity for 10 years after approval and protocol assistance from EMA.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
On Oct. 17, 2023, Lisata Therapeutics announced that the European Medicines Agency (EMA) granted orphan drug designation to LSTA1, Lisata’s lead product candidate for pancreatic cancer treatment. As of the publication of this article, LSTA1 has several ongoing and planned clinical studies conducted globally. These studies use a variety of solid tumor types, including pancreatic cancer, with a range of anti-cancer regimens.
LSTA1 is an investigational drug intended to aid co-administered or tethered anti-cancer drugs to more effectively penetrate solid tumors by activating a novel uptake pathway. LSTA1 activates the pathway in a tumor-specific way, potentially modifying the tumor microenvironment and making tumors more venerable to immunotherapies. There is significant non-clinical data showing LSTA1 enhancing delivery of a variety of existing and emerging anti-cancer therapies, including immunotherapies, chemotherapeutics, and RNA-based therapeutics.
The orphan drug designation is given to drugs and biologics that treat rare disease, which affect no greater than five in 10,000 people in the European Union. The designation is based on a positive opinion from the EMA Committee for Orphan Medicinal Products. The companies of eligible products receive EU marketing exclusivity for 10 years after approval, possible fee reductions, and protocol assistance from EMA.
“To date, LSTA1 has demonstrated favorable safety, tolerability, and activity to enhance delivery of standard-of-care chemotherapy for patients with metastatic pancreatic cancer,” said Kristen K. Buck, M.D., executive vice president of R&D and Chief Medical Officer of Lisata, in a press release. “Obtaining orphan drug designation from the EMA reinforces our belief that LSTA1 offers major improvement in treating patients with this terrible disease. We are excited by the promise of LSTA1 for the treatment of pancreatic cancer and other solid tumors and are committed to advancing our development programs with the goal of providing a benefit to patients.”
Source: Lisata Therapeutics
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
